About the job
Department: CMC
Location: Remote with at least 50% travel to site for meetings in Guangzhou, China
Employment Type: Full-time
Position Summary:
Join the leadership team at Angitia as the Executive Director/Vice President of CMC Process R&D, where you will spearhead the strategic management and execution of early-stage development for innovative biologic products, including monoclonal antibodies (mAb), bispecifics, and antibody-drug conjugates (ADC). You will lead critical activities from cell line selection to cGMP production for Phase I and Phase II manufacturing. This pivotal role involves close collaboration with other senior leaders in Clinical Development, CMC Operations, and Project Management to align with Angitia’s long-term vision. Reporting directly to the CTO, you will serve as the primary liaison for the CMC team based in China and be responsible for all aspects of CMC activities through Phase I/II clinical supply. This includes leading technical efforts across Drug Substance (DS), Drug Product (DP), Analytical Development, Cell Line Development, and formulation development. You will also oversee technology transfer activities for late-stage processes (Phase III and BLA). Be a part of Angitia’s mission to translate groundbreaking science into impactful therapies for patients.

